87 related articles for article (PubMed ID: 11371940)
21. Inducible nitric oxide synthase and bcl-2 expression in nasopharyngeal cancer: correlation with outcome of patients after radiotherapy.
Jayasurya A; Dheen ST; Yap WM; Tan NG; Ng YK; Bay BH
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):837-45. PubMed ID: 12788193
[TBL] [Abstract][Full Text] [Related]
22. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer.
Phan TP; Syed AM; Puthawala A; Sharma A; Khan F
J Urol; 2007 Jan; 177(1):123-7; discussion 127. PubMed ID: 17162020
[TBL] [Abstract][Full Text] [Related]
23. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
[TBL] [Abstract][Full Text] [Related]
24. High dose rate and external beam radiotherapy in locally advanced prostate cancer.
Viani GA; Pellizzon AC; GuimarĂ£es FS; Jacinto AA; dos Santos Novaes PE; Salvajoli JV
Am J Clin Oncol; 2009 Apr; 32(2):187-90. PubMed ID: 19307949
[TBL] [Abstract][Full Text] [Related]
25. Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
Colecchia M; Frigo B; Del Boca C; Guardamagna A; Zucchi A; Colloi D; Leopardi O
J Clin Pathol; 1997 May; 50(5):384-8. PubMed ID: 9215120
[TBL] [Abstract][Full Text] [Related]
26. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
[TBL] [Abstract][Full Text] [Related]
27. The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer.
D'Alimonte L; Helou J; Sherman C; Loblaw A; Chung HT; Ravi A; Deabreu A; Zhang L; Morton G
Brachytherapy; 2015; 14(3):309-14. PubMed ID: 25466361
[TBL] [Abstract][Full Text] [Related]
28. Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT.
Pe ML; Trabulsi EJ; Kedika R; Pequignot E; Dicker AP; Gomella LG; Valicenti RK
Urology; 2009 Jun; 73(6):1328-34. PubMed ID: 19376564
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue.
Xie X; Clausen OP; De Angelis P; Boysen M
Cancer; 1999 Sep; 86(6):913-20. PubMed ID: 10491515
[TBL] [Abstract][Full Text] [Related]
30. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
31. High dose combination radiotherapy for the treatment of localized prostate cancer.
Zeitlin SI; Sherman J; Raboy A; Lederman G; Albert P
J Urol; 1998 Jul; 160(1):91-5; discussion 95-6. PubMed ID: 9628612
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.
Santini D; Tonini G; Vecchio FM; Borzomati D; Vincenzi B; Valeri S; Antinori A; Castri F; Coppola R; Magistrelli P; Nuzzo G; Picciocchi A
J Clin Pathol; 2005 Feb; 58(2):159-65. PubMed ID: 15677536
[TBL] [Abstract][Full Text] [Related]
34. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
35. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.
Ragde H; Korb LJ; Elgamal AA; Grado GL; Nadir BS
Cancer; 2000 Jul; 89(1):135-41. PubMed ID: 10897010
[TBL] [Abstract][Full Text] [Related]
36. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
37. Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review).
Szostak MJ; Kyprianou N
Oncol Rep; 2000; 7(4):699-706. PubMed ID: 10854529
[TBL] [Abstract][Full Text] [Related]
38. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma.
Yamoah K; Eldredge-Hindy HB; Zaorsky NG; Palmer JD; Doyle LA; Sendecki JA; Hesney AA; Harper L; Repka M; Showalter TN; Hurwitz MD; Dicker AP; Den RB
Brachytherapy; 2014; 13(5):456-64. PubMed ID: 24953945
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer.
Zelefsky MJ; Whitmore WF
J Urol; 1997 Jul; 158(1):23-9; discussion 29-30. PubMed ID: 9186315
[TBL] [Abstract][Full Text] [Related]
40. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.
Potters L; Torre T; Ashley R; Leibel S
J Clin Oncol; 2000 Mar; 18(6):1187-92. PubMed ID: 10715287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]